Importance: Research on the relationship between CYP2C19 genetic variations and the clinical outcomes of individuals with mild stroke or transient ischemic attack who are taking clopidogrel is limited.
The goal is to determine whether CYP2C19 genetic variations are associated with the clinical outcomes of clopidogrel-treated patients who have experienced a mild stroke or transient ischemic attack.
Interventions: In the trial, patients with acute mild ischemic stroke or transient ischemic attack were randomly assigned to receive aspirin alone or clopidogrel in combination with aspirin.
Principal results and metrics The main success result was a new stroke. A composite of new composite vascular events served as the secondary efficacy outcome (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death). The result for safety was bleeding.
The use of clopidogrel plus aspirin compared to aspirin alone decreased the risk of a second stroke only in the subset of patients who were not carriers of the CYP2C19 loss-of-function alleles in patients with mild ischemic stroke or transient ischemic attack. Conclusions and significance. These results suggest that the CYP2C19 genotype contributes to the effectiveness of this therapy.
<h3>What is
transient ischemic attack?</h3>
A stroke known as a transient ischemic attack (TIA) only lasts a short while. When a portion of the brain's blood supply is momentarily cut off, it occurs. Similar to other stroke symptoms, TIA symptoms do not remain as long. Numbness or weakness, especially on one side of the body, are some of the sudden symptoms.
To learn more about transient ischemic attack with the help of given link:
https://brainly.ph/question/13120937
#SPJ4
